Biotechnology
GLPG
23.00
price down icon0.04%   -0.01
after-market Handel nachbörslich: 23.00

Galapagos Nv Adr (GLPG)
full-star
loading
Überblick Nachrichten Preisverlauf Optionskette Forum Prognose
Schlusskurs vom Vortag:
$23.01
Offen:
$23
24-Stunden-Volumen:
205.82K
Relative Volume:
0.80
Marktkapitalisierung:
$1.52B
Einnahmen:
$282.04M
Nettoeinkommen (Verlust:
$221.88M
KGV:
6.8334
EPS:
3.3658
Netto-Cashflow:
$-449.57M
1W Leistung:
-2.95%
1M Leistung:
-16.36%
6M Leistung:
-13.76%
1J Leistung:
-38.78%
1-Tages-Spanne:
Value
$22.91
$23.15
1-Wochen-Bereich:
Value
$22.90
$24.04
52-Wochen-Spanne:
Value
$22.90
$40.34

Galapagos Nv Adr Stock (GLPG) Company Profile

Name
Firmenname
Galapagos Nv Adr
Name
Sektor
Healthcare (1173)
Name
Branche
Biotechnology (678)
Name
Telefon
-
Name
Adresse
-
Name
Mitarbeiter
646
Name
Twitter
@GalapagosGlobal
Name
Nächster Verdiensttermin
2024-10-30
Name
Neueste SEC-Einreichungen
Name
GLPG's Discussions on Twitter

Vergleichen Sie GLPG mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
GLPG
Galapagos Nv Adr
 23.00 1.52B 282.04M 221.88M -449.57M 3.3658
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
 461.68 118.90B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
 672.98 73.95B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
 655.13 39.81B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
 271.31 34.99B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
 123.77 29.67B 3.30B -501.07M 1.03B -2.1146

Galapagos Nv Adr Stock (GLPG) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-11-20 Herabstufung Kepler Hold → Reduce
2024-09-09 Eingeleitet Leerink Partners Market Perform
2024-08-02 Herabstufung Raymond James Outperform → Mkt Perform
2024-03-28 Herabstufung BofA Securities Neutral → Underperform
2024-03-07 Fortgesetzt Morgan Stanley Equal-Weight
2023-08-24 Herabstufung Citigroup Buy → Neutral
2023-05-05 Hochstufung Raymond James Mkt Perform → Outperform
2023-01-23 Hochstufung Jefferies Underperform → Hold
2022-11-07 Herabstufung Raymond James Outperform → Mkt Perform
2022-09-09 Herabstufung Morgan Stanley Overweight → Equal-Weight
2022-01-27 Hochstufung Citigroup Neutral → Buy
2021-08-19 Herabstufung Barclays Overweight → Equal Weight
2021-08-06 Herabstufung Deutsche Bank Buy → Hold
2021-04-20 Eingeleitet Deutsche Bank Buy
2021-04-14 Hochstufung Barclays Equal Weight → Overweight
2021-02-23 Hochstufung BofA Securities Underperform → Neutral
2021-02-19 Hochstufung Raymond James Mkt Perform → Outperform
2021-02-11 Herabstufung Citigroup Buy → Neutral
2021-01-19 Hochstufung Morgan Stanley Equal-Weight → Overweight
2020-11-19 Eingeleitet Maxim Group Buy
2020-10-21 Herabstufung Goldman Neutral → Sell
2020-08-25 Herabstufung Jefferies Buy → Hold
2020-08-24 Herabstufung H.C. Wainwright Buy → Neutral
2020-08-19 Herabstufung Barclays Overweight → Equal Weight
2020-08-19 Hochstufung Citigroup Neutral → Buy
2020-07-10 Herabstufung Stifel Buy → Hold
2020-03-30 Hochstufung Jefferies Hold → Buy
2020-03-18 Hochstufung RBC Capital Mkts Underperform → Sector Perform
2020-02-25 Herabstufung Cantor Fitzgerald Overweight → Neutral
2020-02-24 Herabstufung BofA/Merrill Neutral → Underperform
2020-02-20 Herabstufung RBC Capital Mkts Sector Perform → Underperform
2020-01-06 Herabstufung JP Morgan Overweight → Neutral
2019-12-18 Herabstufung Citigroup Buy → Neutral
2019-12-17 Herabstufung Morgan Stanley Overweight → Equal-Weight
2019-12-13 Herabstufung Credit Suisse Outperform → Neutral
2019-12-02 Eingeleitet BofA/Merrill Neutral
2019-09-09 Fortgesetzt Morgan Stanley Overweight
2019-07-31 Hochstufung UBS Neutral → Buy
2019-07-29 Herabstufung Jefferies Buy → Hold
Alle ansehen

Galapagos Nv Adr Aktie (GLPG) Neueste Nachrichten

pulisher
Jan 21, 2025

Galapagos To Spin Off Innovative Medicines Business - Forbes

Jan 21, 2025
pulisher
Jan 08, 2025

Galapagos Unveils 2025 Split To Accelerate Innovation, Sharpen Strategic Focus - Benzinga

Jan 08, 2025
pulisher
Nov 20, 2024

Galapagos stock downgraded to Reduce on strategic concerns - Investing.com

Nov 20, 2024
pulisher
Nov 20, 2024

Galapagos stock downgraded to Reduce on strategic concerns By Investing.com - Investing.com South Africa

Nov 20, 2024
pulisher
Nov 14, 2024

Belgium shares higher at close of trade; BEL 20 up 0.58% - MSN

Nov 14, 2024
pulisher
Nov 04, 2024

Deutsche Bank maintains Hold on Galapagos, reducing target with key updates months away - Investing.com

Nov 04, 2024
pulisher
Nov 01, 2024

Earnings call: Galapagos reports solid Q3 progress, eyes IND studies By Investing.com - Investing.com South Africa

Nov 01, 2024
pulisher
Nov 01, 2024

Earnings call: Galapagos reports solid Q3 progress, eyes IND studies - Investing.com

Nov 01, 2024
pulisher
Nov 01, 2024

Galapagos stock outlook cautious with clinical readouts on the horizon, says Morgan Stanley - Investing.com

Nov 01, 2024
pulisher
Oct 30, 2024

Galapagos ADR earnings missed by $0.05, revenue topped estimates - Investing.com UK

Oct 30, 2024
pulisher
Sep 09, 2024

Leerink Partners gives Market Perform rating to Galapagos NV stock, flags R&D challenges - Investing.com

Sep 09, 2024
pulisher
Aug 27, 2024

Navigating GLPG Stock: Galapagos NV ADR Journey - The InvestChronicle

Aug 27, 2024
pulisher
Aug 26, 2024

Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket - Benzinga

Aug 26, 2024
pulisher
Aug 23, 2024

Galapagos (GLPG) Up on FDA Nod to Begin Phase I/II Lymphoma Study - Yahoo Finance

Aug 23, 2024
pulisher
Aug 03, 2024

Morgan Stanley cuts Galapagos NV target to $32 from $35 - Investing.com

Aug 03, 2024
pulisher
Aug 02, 2024

Earnings call: Galapagos focuses on oncology and immunology in H1 2024 report - Investing.com

Aug 02, 2024
pulisher
Jul 15, 2024

Belgium stocks lower at close of trade; BEL 20 down 0.90% - Investing.com

Jul 15, 2024
pulisher
May 30, 2024

Adaptimmune and Galapagos partner on cancer therapy - Investing.com

May 30, 2024
pulisher
Apr 17, 2024

Citi lowers Galapagos NV shares target amid restructuring and pipeline investments By Investing.com - Investing.com

Apr 17, 2024
pulisher
Mar 07, 2024

Morgan Stanley sets Galapagos stock at equalweight, $38 price target - Investing.com

Mar 07, 2024
pulisher
Jan 27, 2022

Galapagos Surges On New CEO and Upgrade News - Investing.com

Jan 27, 2022
pulisher
Dec 30, 2020

Galapagos: Market Values Pipeline Below $0 (NASDAQ:GLPG) - Seeking Alpha

Dec 30, 2020
pulisher
Aug 19, 2020

The Daily Biotech Pulse: Gilead's Filgotinib Stumbles With FDA, J&J Laps Up Momenta In $6.5B Deal, 2 IPOs - Benzinga

Aug 19, 2020
pulisher
Jan 17, 2020

The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares - Yahoo Finance

Jan 17, 2020
pulisher
Apr 30, 2019

World’s Top-Selling Drugs: Gilead Sciences, Inc. Sovaldi Closes In On AbbVie Inc Humira - Crypto Coins Tribune

Apr 30, 2019
pulisher
Apr 17, 2019

Galapagos NV (GLPG) Stock Price, Trades & News - GuruFocus.com

Apr 17, 2019
pulisher
Jul 27, 2018

AIM tech shares that broke America - Interactive Investor

Jul 27, 2018
pulisher
Jul 07, 2017

Galapagos Is More Attractive–But Don’t Buy It Just Yet - Barron's

Jul 07, 2017
pulisher
Dec 30, 2015

The 5 Best-Performing Non-S&P Stocks of 2015 - Forbes

Dec 30, 2015
pulisher
Jul 31, 2015

GalapagosAll Time High - Seeking Alpha

Jul 31, 2015

Finanzdaten der Galapagos Nv Adr-Aktie (GLPG)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Ähnlich wie GLPG

biotechnology MRNA
$39.42
price down icon 3.95%
biotechnology UTHR
$351.17
price down icon 0.32%
biotechnology SMMT
$21.50
price down icon 3.85%
biotechnology NEUP
$5.30
price down icon 2.03%
biotechnology ONC
$224.99
price down icon 0.84%
biotechnology BNTX
$123.77
price up icon 2.39%
In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters
Kapitalisierung:     |  Volumen (24h):